Navigation Links
AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform
Date:9/17/2008

AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease. The combination of this gene with AMT's proprietary adeno-associated virus (AAV) gene therapy platform could potentially allow the development of an effective, long-term treatment for this progressive and crippling disease.

Parkinson's disease is the second most common neurodegenerative disease. It usually affects people over 65 with an estimated total of 4.5 million patients worldwide. Due to increasing life expectancy of the general population, the number of patients with Parkinson's disease is expected to double to around 9 million patients between now and the year 2030.

Patients with Parkinson's disease slowly lose control of their muscles, resulting in tremors, stiffness, slowness of movement, and lack of coordination and thus in a serious loss of quality of life. Parkinson's is caused by degeneration and death of nerve cells in a specific part of the brain. These cells produce dopamine, a substance necessary for communication between nerve cells involved in the coordination of movement. Current therapies are limited to treatment of symptoms. There are no therapies available that slow down or halt the progression of the disease.

A new way to deliver the GDNF gene

"This license from Amgen offers us a unique opportunity to combine our gene technology and know-how with the GDNF gene as a tool to create a potential breakthrough in the treatment for this common and severely debilitating disease," said Ronald Lorijn, CEO of AMT "We believe our gene therapy approach could be an effective way to deliver the gene to the regions of the brain affected by Parkinson's disease."

Protect and improve nerve cells with GDNF


'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
2. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
3. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
4. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
5. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
8. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
9. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
10. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
11. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BOSTON, May 6, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... financial results for the three-month period ended March 31, ... were $8.3 million, an increase of 19% as compared ... , Product revenues increased 41% year-over-year, enabled by ... shipments to Merck Serono in the fourth quarter of ...
(Date:5/6/2015)... 6, 2015 First ... dolutegravir and rilpivirine   ViiV ... III clinical trial programme to evaluate the safety ... [1] ) as maintenance therapy for adult patients ... replicate studies evaluating 48 week viral suppression with ...
(Date:5/6/2015)... 2015 Woodford Patient Capital ... Trust and the Bill & Melinda Gates Foundation ... a leading monoclonal antibody biopharmaceutical company, announced today ... million to complete a US$90 million Series B ... Woodford Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin ...
Breaking Medicine Technology:Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
(Date:5/6/2015)... has opened press registration for TU-Automotive Detroit as the ... headlines of major publications world-wide. With 150+ speakers from ... to share their visions for the future of connected ... to go behind the scenes and hear major automakers’ ... year we’re releasing a preview of all the major ...
(Date:5/6/2015)... Water NSW (New South ... manage and distribute imagery, LiDAR, and Elevation Data within ... driest continents on earth, and the need to ensure ... erratic seasonal rainfalls has driven the development of several ... manages raw water supplies for NSW, including high quality ...
(Date:5/6/2015)... May 06, 2015 Cloud security companies ... announced a strategic partnership to help small-to-medium businesses secure ... two industry-leading companies are teaming up to transition SafeMonk ... , “We’re thrilled to welcome SafeMonk users to the ... the people behind SafeMonk, the global powerhouse SafeNet (now ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... 2015 Most people in the United States ... other care after age 65. But less than half of ... or even talking about it, reports the May 2015 ... two problems. One is losing control over the care they'll ... Dr. David Grabowski, a professor of health care policy at ...
Breaking Medicine News(10 mins):Health News:Press Registration for TU-Automotive Detroit Now Open 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2
... concern over discrepancies in official data for key sectors ... called for a revamp of the national statistical system ... the administrative set up and traditional records, the (statistical) ... changing times," Manmohan Singh said in his address at ...
... the Institute Pasteur has recently shown that the tuberculosis ... fat cells. //This formidable pathogen is protected against even ... it may remain dormant for years. ,This ... possible strategies for fighting tuberculosis. Attempts to eradicate the ...
... research centre is being planned at the Pune-based ... diseases//, a general says. ,"Stem cell therapy ... will be the futuristic treatment replacing drug therapy ... diabetes, Parkinson's disease, epilepsy, multiple sclerosis, eye and ...
... San Diego biologists have shown that the chemical language ... electrical activity in the developing nervous system. The findings ... as a treatment for a wide range of brain ... the early on-line edition of the journal Proceedings of ...
... Christmas is indeed a ‘ubiquitous’ festival, as it is celebrated ... an estimated 26 million Indian homes.// The joys of the ... are seen making the most of the special bargains and ... time for the celebration. Plans are afoot in great enthusiasm ...
... director of Clarkson's Center for Air Resources Engineering ... on airborne pollution who serves on the Environmental ... also one of scores of health officials and ... the casual link between pollutants and respiratory illnesses. ...
Cached Medicine News:Health News:Manmohan Calls for Statistical Reforms in Healthcare and Education 2Health News:Tuberculosis: The Bacillus Takes Refuge in Adipose Cells 2Health News:Military College to Set Up Stem Cell Research Centre 2Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Research on to Find Link Between Airborne Pollutants and Respiratory Illness 2
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Processor is a primary component of an ... processing, sampling, and slide preparation all ... MonoPrep LBP Processor produces high-quality sample slides ... range of cytology specimen types. It processes ...
... Binding, Graduated Pipet Tips - 2l - 200l. ... referenced. Produced & packaged completely by automation. RNAse ... packaged 96 tips/rack and 10 racks/cs. AVR2 is ... racks/cs. AVR3 is the Stacked Rack packaged 96 ...
Medicine Products: